top of page

Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting

February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy at the 2019 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting taking place February 22nd - 25th in San Francisco. PVX108 is a peptide-based immunotherapy designed to safely induce immune tolerance to peanut allergens without the safety limitations of other approaches that expose patients to intact, allergenic protein that may cause allergic reactions or anaphylaxis during treatment.

bottom of page